The New York Times
By RONI CARYN RABIN
Published: February 24, 2010
Women older than 40 are unlikely to get much benefit from the vaccine for the virus that causes cervical cancer, a new study reports.
The vaccine for human papillomavirus, or HPV, is recommended for women up to age 26 and girls as young as 9. To determine whether older women might be protected as well, the new study looked at patterns of HPV infection as women age, said Dr. Ana Cecilia Rodríguez,...
Insciences organisation
Published on 25 February 2010, 03:39
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a phase III study showed the combination of Avastin (bevacizumab) and chemotherapy followed by maintenance use of Avastin increased the time women with advanced ovarian cancer lived without their disease worsening (progression-free survival or PFS) compared to chemotherapy alone. A preliminary assessment of safety noted adverse events previously observed in pivotal...
The Sydney Morning Herald
DANNY ROSE
February 23, 2010
Source: AAP
Experts can report some "positive news" on ovarian cancer, as research shows a slight decrease in incidence of the often deadly and difficult to detect disease.
The Australian Institute of Health and Welfare and the National Breast and Ovarian Cancer Centre (NBOCC) have jointly released their latest data on the cancer.
It shows that in 2006 just over 1220 Australian...
Top Doctors to Present Results of FDA Clinical Trial of Guided Therapeutics’ Cervical Cancer Detection Technology at Scientific Meeting
Business Wire
February 23, 2010 08:45 AM Eastern Time
Five Presentations Scheduled for American Society for Colposcopy and Cervical Pathology Meeting
NORCROSS, Ga.--(BUSINESS WIRE)--Results of the U.S. Food and Drug Administration (FDA) pivotal clinical trial for the Guided Therapeutics, Inc. (GT) (Pink Sheets: GTHP)...
Vaccine demonstrates high efficacy against HPV types 16 and 18 in 18-25 year old women
New data presented this week at the EUROGIN conference support that young adult women, a population group not typically targeted for cervical cancer immunization, could benefit from the vaccine.
The primary focus of most current recommendations is to vaccinate young girls before the onset of sexual...
Blog Categories
Abraxane (Paclitaxel Albumin-stabilized Nanoparticle Formulation)
(2)
